172 related articles for article (PubMed ID: 36929466)
21. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
22. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
23. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
[TBL] [Abstract][Full Text] [Related]
24. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
[TBL] [Abstract][Full Text] [Related]
25. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
26. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract][Full Text] [Related]
27. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
Feng J; Yang H; Zhang Y; Wei H; Zhu Z; Zhu B; Yang M; Cao W; Wang L; Wu Z
Oncogene; 2017 Oct; 36(42):5829-5839. PubMed ID: 28604752
[TBL] [Abstract][Full Text] [Related]
28. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma.
Zhao W; Liu L; Li X; Xu S
Int Immunopharmacol; 2022 Sep; 110():109031. PubMed ID: 35839564
[TBL] [Abstract][Full Text] [Related]
29. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
30. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
31. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
Cui Y; Li J; Zhang P; Yin D; Wang Z; Dai J; Wang W; Zhang E; Guo R
J Exp Clin Cancer Res; 2023 Jun; 42(1):146. PubMed ID: 37303063
[TBL] [Abstract][Full Text] [Related]
32. The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis.
Zhou X; Yan Z; Hou J; Zhang L; Chen Z; Gao C; Ahmad NH; Guo M; Wang W; Han T; Chang T; Kang X; Wang L; Liang Y; Li X
Oncogene; 2024 Feb; 43(7):495-510. PubMed ID: 38168654
[TBL] [Abstract][Full Text] [Related]
33. ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity.
Chen K; Hong C; Kong W; Li G; Liu Z; Zhu K; Lu C; Si P; Gao P; Ning G; Zhang R
Cancer Cell Int; 2024 Feb; 24(1):86. PubMed ID: 38402174
[TBL] [Abstract][Full Text] [Related]
34. Circular RNA circ_0067741 regulates the Hippo/YAP pathway to suppress lung adenocarcinoma progression by targeting microRNA-183-5p.
Mo J; Nie H; Zeng C; Han H; Xu P; Shi X
Bioengineered; 2022 Apr; 13(4):10165-10176. PubMed ID: 35435136
[TBL] [Abstract][Full Text] [Related]
35. Small molecule TKI inhibitors affect the development of non-small cell carcinoma through HIPPO/YAP/PD-L1.
Lei L; Weidong Z
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):117-122. PubMed ID: 35818263
[TBL] [Abstract][Full Text] [Related]
36. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
37. Yes associated protein is a poor prognostic factor in well-differentiated lung adenocarcinoma.
Kim MH; Kim YK; Shin DH; Lee HJ; Shin N; Kim A; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Int J Clin Exp Pathol; 2015; 8(12):15933-9. PubMed ID: 26884866
[TBL] [Abstract][Full Text] [Related]
38. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
39. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Zhu P; Kang G; Jiao Y; Gui C; Fan H; Li X; Jia Y; Zhang L; Ma X
Hum Cell; 2022 Jul; 35(4):1207-1218. PubMed ID: 35593989
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]